Abstract
INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine if tethering affected Nrf2 degradation. Data is presented showing that Nrf2 is degraded by the ubiquitin-proteasome pathway. Nrf2 co-immunoprecipitated with a HA tagged ubiquitin polymer and accumulated in cells expressing inactive ubiquitin activating enzyme El. Inhibition of proteasome activity resulted in accumulation of Nrf2. The rate of Nrf2 degradation, measured under conditions where the majority of Nrf2 was not tethered, exhibited a T1/2 of approximately 3 h. Over-expression of human INrf2, KIAA0132, blocked Nrf2 conjugation to the ubiquitin polymer and blocked Nrf2 degradation. These results suggest that association of Nrf2 with INrf2 inhibits ubiquitin-proteasome degradation of Nrf2. Maintaining the majority of Nrf2 in a tethered form, resistant to ubiquitin-proteasome dependent degradation, allows a pool of Nrf2 to be available for rapid Nrf2/ARE-dependent gene transcription following stress mediated release from INrf2. Further, the observation that free Nrf2 is degraded by the ubiquitin proteasome pathway provides a potential mechanism by which ARE-dependent gene transcription is attenuated after induction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chan JY, Kwong M . 2000 Biochim. Biophys. Acta 1517: 19–26
Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, Henderson CJ, Wolfb CR, Moffat GJ, Itoh K, Yamamoto M, Hayes JD . 2002 Biochem. J. 365: Pt2 405–416
Chowdary DR, Dermody JJ, Jha KK, Ozer HL . 1994 Mol. Cell. Biol. 14: 1997–2003
Ciechanover A . 1998 EMBO J. 17: 7151–7160
Dhakshinamoorthy S, Jaiswal AK . 2001 Oncogene 20: 3906–3917
Favreau LV, Pickett CB . 1991 J. Biol. Chem. 266: 4556–4561
Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL . 1995 Science 268: 726–731
Friling RS, Bensimon A, Tichauer Y, Daniel V . 1990 Proc. Natl. Acad. Sci. USA 87: 6258–6262
Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M . 1999 Genes Dev. 13: 76–86
Kwak MK, Itoh K, Yamamoto M, Kensler TW . 2002 Mol. Cell. Biol. 22: 2883–2892
McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, Wolf CR, Cavin C, Hayes JD . 2001 Cancer Res. 61: 3299–3307
Meister A, Anderson ME . 1983 Annu. Rev. Biochem. 52: 711–760
Moi P, Chan K, Asunis I, Cao A, Kan YW . 1994 Proc. Natl. Acad. Sci. USA 91: 9926–9930
Mulcahy RT, Wartman MA, Bailey HH, Gipp JJ . 1997 J. Biol. Chem. 272: 7445–7454
Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara A . 1992 Nature 360: 597–599
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW . 2001 Proc. Natl. Acad. Sci. USA 98: 3410–3415
Sekhar KR, Soltaninassab SR, Borrelli MJ, Xu ZQ, Meredith MJ, Domann FE, Freeman ML . 2000 Biochem. Biophys. Res. Commun. 270: 311–317
Sekhar KR, Spitz DR, Harris S, Nguyen TT, Meredith MJ, Holt JT, Guis D, Marnett LJ, Summar ML, Freeman ML . 2002 Free Radic. Biol. Med. 32: 650–662
Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE . 2000 Mol. Cell. 5: 403–410
Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE . 1999 J. Biol. Chem. 274: 15194–15202
Treier M, Staszewski LM, Bohmann D . 1994 Cell 78: 787–798
Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ . 2001 Nature 412: 346–351
Wild AC, Gipp JJ, Mulcahy T . 1998 Biochem. J. 332: 373–381
Wild AC, Moinova HR, Mulcahy RT . 1999 J. Biol. Chem. 274: 33627–33636
Wolf CR . 2001 Proc. Natl. Acad. Sci. USA 98: 2941–2943
Xie Y, Varshavsky A . 2000 Proc. Natl. Acad. Sci. USA 97: 2497–2502
Acknowledgements
It is a pleasure to acknowledge the expert technical assistance of Waraporn Decha-Umphai. This investigation was supported in part by PHS/NIH grants CA-38079 and P30ES00267 pilot project funds.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sekhar, K., Yan, X. & Freeman, M. Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene 21, 6829–6834 (2002). https://doi.org/10.1038/sj.onc.1205905
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205905
Keywords
This article is cited by
-
Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review
Inflammopharmacology (2021)
-
Nrf2 in liver toxicology
Archives of Pharmacal Research (2020)
-
The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases
Biophysical Reviews (2017)
-
Bacillus amyloliquefaciens SC06 alleviates the oxidative stress of IPEC-1 via modulating Nrf2/Keap1 signaling pathway and decreasing ROS production
Applied Microbiology and Biotechnology (2017)
-
Glycosylation enables aesculin to activate Nrf2
Scientific Reports (2016)